This broad-spectrum dry cow therapy goes deep into the udder.

**Cobactan DC**

**References**

**Name:** Cobactan DC / Cephaguard DC, intramammary suspension.

**Active substance:** Cefquinome (as sulphate): 150.0 mg

**Indications for use:** For the treatment of subclinical mastitis at drying off and the prevention of new bacterial infections of the udder during the dry period in the dairy cow caused by the following cefquinome sensitive organisms: *Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus*, coagulase negative staphylococci. **Withdrawal periods:** Meat: 2 days Milk: 49 days after treatment in case of a short dry period less than 7 weeks, 1 day after calving in case of a dry period of more than 7 weeks.

**Pharmacodynamic properties:** The antibacterial drug Cefquinome is a broad spectrum cephalosporin of the fourth generation which acts by inhibition of cell wall synthesis. It is bactericidal and is characterised by its broad therapeutic spectrum of activity and a high stability against penicillinases and beta-lactamases. *In vitro* activity has been demonstrated against common Gram positive and Gram negative bacteria including *Escherichia coli, Citrobacter spp., Klebsiella spp., Pasteurella spp., Proteus spp., Salmonella spp., Serratia marcescens, Arcanobacterium pyogenes, Corynebacterium spp., Staphylococcus aureus, coagulase negative Staphylococci, Streptococcus dysgalactiae, Streptococcus agalactiae, Streptococcus uberis, Streptococcus bovis*. Following bacterial species: *Staphylococcus aureus, coagulase negative Staphylococci, Streptococcus uberis, Streptococcus dysgalactiae and Streptococcus agalactiae* isolated from a field study conducted between 2000 and 2002 in Germany, France, Belgium and the Netherlands proved to be susceptible to cefquinome with MIC values between ≤ 0.008 µg/ml and 2.0 µg/ml. **Contraindications:** Not to be administered to animals which are known to be hypersensitive to cephalosporin antibiotics or other ß-lactam antibiotics. Not to be administered to cows with clinical mastitis.
Think deep.

This broad-spectrum dry cow therapy goes deep into the udder.
Keep cell counts low with a modern dry cow therapy

Cobactan® DC successfully treats intramammary infections whilst reducing somatic cell counts in infected quarters, resulting in higher yields and better quality milk.

This deep acting antibiotic attacks mastitis-causing bacteria deep in the udder whilst preventing new infections during the dry period.

Cobactan DC uses cefquinome, the most advanced cephalosporin antibiotic in veterinary medicine, to improve udder health and reduce somatic cell counts. Cobactan DC’s ability to treat and protect against a broad spectrum of pathogens and its unique formulation make it the most modern and innovative dry cow product available.
Think low.
Broad-spectrum activity results in high cure rates

Cobactan DC’s broad-spectrum activity and high cure rates make it a highly effective dry cow therapy. Its key ingredient, cefquinome, is active against all relevant mastitis pathogens.

Streptococci, staphylococci and coliform bacteria are highly sensitive to cefquinome. These are the most prevalent bacteria causing subclinical mastitis at dry off. Cobactan DC has a high cure rate against gram-positive bacteria as shown in figure 4.

In addition, cefquinome has proven itself worldwide as effective against E. coli and other gram-negative bacilli.

With this wide range of effectiveness and excellent cure rates, Cobactan DC is one of the world’s most powerful dry cow treatments to fight intramammary infections.
Think broad.
Cobactan DC dives deep to treat the entire udder

Cobactan DC effectively differentiates itself amongst dry cow treatments by reaching the entire udder. This new therapy is specially formulated to create optimal size cefquinome particles ensuring a unique level of tissue penetration.\(^{(4)}\)

Trials have demonstrated that following the administration of Cobactan DC, effective levels of cefquinome rapidly penetrate the deep udder tissue, known to be particularly difficult to target.

Furthermore, Cobactan DC’s colloidal silica thickening agent paces the release of the cefquinome to prolong protection during dry off. The result of this modern formulation is a highly favourable pharmacokinetic profile.

When it’s time to dry off cows, think low. Think
Think deep.